Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1820237 alone or with liraglutide in overweight/obesity
NCT04903509Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1820237 in Overweight and obesity (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of subjects with drug-related adverse events up to 48 days. Started Jun 2021; status: completed.
02
Drugs
BI 1820237
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT04903509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903509.